Cellectar Biosciences has been granted orphan drug designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL) by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development, the company…

The U.S. Patent and Trademark Office awarded Cellectar Biosciences a notice of allowance for a patent covering the use of CLR 131 in multiple myeloma (MM), the company announced today. “This patent…